News

Milan, Italy, 18 February 2026 Benta has announced the acquisition of NerPharMa, a pharmaceutical manufacturing company located in Milan, Italy, from NMS Group. The acquisition marks a significant step in strengthening Benta’s European industrial platform and...

NERVIANO, Italy, 28 July 2025 — NerPharMa (NPM), a renowned Contract Development and Manufacturing Organization (CDMO) specializing in oncology and in immunology, today announced the appointment of Serena Alvino, MBA, CIPP/E, as its new Chief Executive Officer, effective immediately.

Nerviano, Italy – 09 July 2025 – NMS Group S.p.A., the largest oncology-focused R&D organization in Italy, today announced the appointment of Mr. Victor Chu to its Board of Directors, effective immediately. Mr. Chu replaces Mr. Lincoln Pan, who has stepped down from the Board after a period of dedicated and impactful service.

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces today a change to its shareholding structure, leading to a restructured board of directors and statutory auditors. The Fondazione Regionale per la Ricerca Biomedica (FRRB), established by the Lombardy Regional Government with an aim to promote and support biomedical research in the region, has agreed to conclude its investment in NMS Group as minority shareholder.

NerPharMa Srl (NerPharMa, part of the NMS Group),is pleased to announce the appointment of Vittorio Montanaro as Industrial Operation Site Head and member of the Board of Directors (Consiglio di Amministrazione).

NMS Nerviano Bio-Park, today announced the appointment of Marco Dieci as the new Chief Executive Officer, effective immediately. With an exceptional track record in biotechnology, business development and entrepreneurship, Marco is ready to lead SIMIS and Nerviano Bio-Park into an era of unprecedented growth and collaboration.

Nerpharma is pleased to announce the appointment of Claudio Salvagnini as the Deputy CEO, effective immediately.

Since Claudio joined the leadership team earlier this year, he has been a driving force in the recent turning around NerPharMa. As the Deputy CEO, he will play a critical role in shaping the company’s strategic direction and ensuring operational efficiency.

(Click the title for the complete article)

NerPharMa Srl (part of NMS group), a leading Contract Development and Manufacturing Organization (CDMO), is pleased to announce the appointment of Vittorio Montanaro as new Head of Quality, effective immediately. In this role, Vittorio will lead the Quality Assurance, Quality Control and Regulatory Affairs to ensure the highest standards of quality, safety and compliance across NerPharMa’s extensive range of services, offered through both Drug Substances and Drug Product divisions. Vittorio will cover also the role of Qualified Person.

(Click the title for the complete article)

NMS group has joined the WHP program since 2017. The Workplace Health Promotion (WHP) is the combined efforts of employers, employees and society to improve the health and well-being of people at work. The promotion of a comfortable and healthy workplace has been one of the goals of NMS group since 2017.
(Click the title for the complete article)

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)